Given Imaging Ltd., maker of PillCam capsule endoscopes, will be taking its technology to a totally different plane. With the help of European consortium (members: Zarlink Semiconductor (Sweden and UK), Fraunhofer Institute for Biomedical Engineering, Israelitic Hospital and Indivumed (Germany), Imperial College of Science, Technology and Medicine (London, England), ITC-irst Research Institute (Italy), The Hebrew University of Jerusalem, Novamed and Ernst &Young of Israel), the company will be developing a capsule endoscopic system capable of molecular diagnostics to screen for GI cancers. The objective of the NEMO project is to increase patient compliance with currently recommended screening guidelines by developing an advanced cancer screening system that is patient-friendly, highly sensitive and specific for early detection of cancer. To achieve this NEMO will converge optical technologies with Nano-technologies, biosensing and maneuvering technologies to create a unique PillCam capsule endoscope capable of secretion analysis and the detection of marked and deep tissue disorders. The consortium believes the combination of the image and molecular analysis to mark the tumor may provide a novel and effective medical device for mass screening for GI cancer.
[Source: medgadget][More: globes]
No comments:
Post a Comment